Literature DB >> 10480450

Correlation between the administered dose of DHEA and serum levels of DHEA and DHEA-S in human volunteers: analysis of published data.

S Tummala1, F Svec.   

Abstract

OBJECTIVES: Studies from both experimental animals and humans suggest that administration of exogenous DHEA may have beneficial endocrine-metabolic, immunologic and neurologic effects. Several groups have administered DHEA to humans, but to the best of our knowledge, no one at this point has published a summary of the relationship between the administered dose of DHEA and the serum levels of steroids attained.
DESIGN: We summarize the relationship between the administered dose of DHEA and the resulting serum level of DHEA and DHEA-S, in humans, from 18 published articles.
RESULTS: Serum levels of DHEA and DHEA-S increase with increasing doses. Doses above 50 mg/day result in levels that are at or above the upper limit of normal for healthy young adults. At doses above 300 mg/day the increment of serum DHEA and DHEA-S appears to reach a plateau.
CONCLUSIONS: Those wanting to use supplemental DHEA might consider that doses of 300 mg/day are maximal; they clearly result in supraphysiologic concentrations and above this level doses may have increased side effects without significantly increasing the effective level of serum hormone.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10480450     DOI: 10.1016/s0009-9120(99)00021-1

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  7 in total

1.  Effects of dehydroepiandrosterone (DHEA) on cardiovascular risk factors in older women with frailty characteristics.

Authors:  R S Boxer; A Kleppinger; J Brindisi; R Feinn; J A Burleson; A M Kenny
Journal:  Age Ageing       Date:  2010-05-18       Impact factor: 10.668

2.  The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy.

Authors:  Julio Rosenstock; Salomon Banarer; Vivian A Fonseca; Silvio E Inzucchi; William Sun; Wenqing Yao; Gregory Hollis; Robert Flores; Richard Levy; William V Williams; Jonathan R Seckl; Reid Huber
Journal:  Diabetes Care       Date:  2010-04-22       Impact factor: 17.152

3.  Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension.

Authors:  Sébastien Bonnet; Eric Dumas-de-La-Roque; Hugues Bégueret; Roger Marthan; Michael Fayon; Pierre Dos Santos; Jean-Pierre Savineau; Etienne-Emile Baulieu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-23       Impact factor: 11.205

4.  Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone.

Authors:  Noriyuki Homma; Tetsutaro Nagaoka; Vijaya Karoor; Masatoshi Imamura; Laimute Taraseviciene-Stewart; Lori A Walker; Karen A Fagan; Ivan F McMurtry; Masahiko Oka
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-05-09       Impact factor: 5.464

5.  Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension.

Authors:  Masahiko Oka; Vijaya Karoor; Noriyuki Homma; Tetsutaro Nagaoka; Eiko Sakao; Scott M Golembeski; Jennifer Limbird; Masatoshi Imamura; Sarah A Gebb; Karen A Fagan; Ivan F McMurtry
Journal:  Cardiovasc Res       Date:  2007-02-12       Impact factor: 10.787

6.  Vasodilator effects of dehydroepiandrosterone (DHEA) on fetal pulmonary circulation: An experimental study in pregnant sheep.

Authors:  Dyuti Sharma; Hélène Coridon; Estelle Aubry; Ali Houeijeh; Véronique Houfflin-Debarge; Rémi Besson; Philippe Deruelle; Laurent Storme
Journal:  PLoS One       Date:  2018-06-27       Impact factor: 3.240

Review 7.  Dehydroepiandrosterone: a potential therapeutic agent in the treatment and rehabilitation of the traumatically injured patient.

Authors:  Conor Bentley; Jon Hazeldine; Carolyn Greig; Janet Lord; Mark Foster
Journal:  Burns Trauma       Date:  2019-08-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.